Survival advantage of native and engineered T cells is acquired by mitochondrial transfer from mesenchymal stem cells.

ABSTRACT:

Background

Apoptosis, a form of programmed cell death, is critical for the development and homeostasis of the immune system. Chimeric antigen receptor T (CAR-T) cell therapy, approved for hematologic cancers, retains several limitations and challenges associated with ex vivo manipulation, including CAR T-cell susceptibility to apoptosis. Therefore, strategies to improve T-cell survival and persistence are required. Mesenchymal stem/stromal cells (MSCs) exhibit immunoregulatory and tissue-restoring potential. We have previously shown that the transfer of umbilical cord MSC (UC-MSC)-derived mitochondrial (MitoT) prompts the genetic reprogramming of CD3⁺ T cells towards a T_reg cell lineage. The potency of T cells plays an important role in effective immunotherapy

SUBMITTER: Court AC 

PROVIDER: S-EPMC11429672 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature